Here is the second portfolio which, as with the first, managed to survive after eight weeks in a row of S&P gains; there are fewer positions here, but the key one, EFA, is quite large.
Adma Biologics crashed hard, but I think it has more to go. I’ve been tightening up the stop-loss along the way.





